Apolipoprotein A1 polymorphisms and risk of coronary artery disease: a meta-analysis
More details
Hide details
Submission date: 2016-07-14
Final revision date: 2016-09-06
Acceptance date: 2016-10-01
Online publication date: 2017-01-19
Publication date: 2017-06-08
Arch Med Sci 2017;13(4):813-819
Introduction: It has been reported that APOA1 –75G/A polymorphism might be associated with susceptibility to coronary artery disease (CAD). Owing to mixed and inconclusive results, we conducted a meta-analysis to systematically summarize and clarify the association between APOA1-75G/A polymorphism and the risk of CAD.
Material and methods: A systematic search of studies on the association of single nucleotide polymorphisms (SNP) with susceptibility to CAD was conducted. A total of 9 case-control studies (1864 cases and 1196 controls) on the APOA1-75G/A polymorphism were included.
Results: We observed no statistically significant association between APOA1 –75G/A polymorphism and risk of CAD under the dominant genetic model (AA + AG vs. GG: OR = 1.03, 95% CI: 0.65–1.66), allelic contrast (A vs. G: OR = 0.88, 95% CI: 0.58–1.32), heterozygote model (AG vs. GG: OR = 1.24, 95% CI: 0.81–1.89) or homozygote model (AA vs. GG: OR = 0.52, 95% CI: 0.26–1.05). Significant heterogeneity between individual studies appears in all five models, but a strong association under the recessive genetic model (AA vs. AG + GG: OR = 0.51, 95% CI: 0.28–0.92). In the subgroup analysis by Hardy-Weinberg equilibrium (HWE; the presence or absence of HWE in controls), significantly decreased CAD risk and no significant heterogeneity were observed among controls consistent with HWE. Overall, the APOA1 A allele is one of the protective factors of CAD. A stronger association between APOA1-75G/A polymorphisms and CAD risk was present in the studies consistent with HWE.
Conclusions: The minor allele of the APOA1-75G/A polymorphism is a protective factor for CAD, especially in the studies consistent with HWE.
Journals System - logo
Scroll to top